Navigation Links
New target to enhance anti-cancer drug sensitivity found in translation
Date:6/12/2008

The development of resistance to anticancer chemotherapeutic agents remains a large problem. In some cases, such resistance is associated with altered control of a cellular process known as translation, which is central to the generation of proteins. New data, generated by Jerry Pelletier and colleagues, at McGill University, Montreal, have identified a drug that can enhance the sensitivity of mouse cancer cells to standard anticancer chemotherapeutic agents.

In the study, small molecules were screened for their ability to inhibit the initiation of translation by modifying the function of a protein known as eIF4A, which has a central role in translation initiation. A class of natural drugs known as cyclopenta[b]benzofuran flavaglines were found to have the desired effects and one member of this class of compounds was shown to reverse the resistance of cancer cells to anticancer chemotherapeutic agents in a mouse model of lymphoma. The authors therefore suggest that developing approaches to inhibit translation initiation by targeting eIF4A might provide a way to altering drug resistance in cancers exhibiting altered control of translation initiation.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
3. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
4. U.S. Health Initiative Targets Aging Hispanics
5. Global Health Project targets reducing AIDS among Indias adolescents
6. Study suggests brain tumors need treatment with multiple targeted drugs
7. GP targets on heart disease should be simpler and based more on treatment and prevention
8. T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
9. Chronic infection persists by targeting stromal cell network in lymphoid organs
10. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
11. International Law Enforcement Operation Targets Underground Manufacture of Anabolic Steroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: